Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TEMOZOLOMIDE Cause Malignant neoplasm progression? 779 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 779 reports of Malignant neoplasm progression have been filed in association with TEMOZOLOMIDE (TEMOZOLOMIDE). This represents 4.6% of all adverse event reports for TEMOZOLOMIDE.

779
Reports of Malignant neoplasm progression with TEMOZOLOMIDE
4.6%
of all TEMOZOLOMIDE reports
208
Deaths
125
Hospitalizations

How Dangerous Is Malignant neoplasm progression From TEMOZOLOMIDE?

Of the 779 reports, 208 (26.7%) resulted in death, 125 (16.0%) required hospitalization, and 21 (2.7%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TEMOZOLOMIDE. However, 779 reports have been filed with the FAERS database.

What Other Side Effects Does TEMOZOLOMIDE Cause?

Disease progression (1,562) Death (1,403) Off label use (1,357) Product use in unapproved indication (1,353) Thrombocytopenia (1,300) Drug ineffective (1,131) Nausea (1,071) Neutropenia (809) Fatigue (766) Vomiting (697)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which TEMOZOLOMIDE Alternatives Have Lower Malignant neoplasm progression Risk?

TEMOZOLOMIDE vs TEMSIROLIMUS TEMOZOLOMIDE vs TENAMFETAMINE TEMOZOLOMIDE vs TENAPANOR TEMOZOLOMIDE vs TENECTEPLASE TEMOZOLOMIDE vs TENELIGLIPTIN

Related Pages

TEMOZOLOMIDE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression TEMOZOLOMIDE Demographics